Literature DB >> 15725905

Coagulation factor V: a plethora of anticoagulant molecules.

Michael Kalafatis1.   

Abstract

PURPOSE OF REVIEW: Thrombin is necessary for survival and is produced after activation of prothrombin by prothrombinase at the site of a vascular injury. While the enzyme component of prothrombinase alone, factor Xa, bound to a membrane surface can activate prothrombin, incorporation of the cofactor molecule, factor Va, into prothrombinase results in a five orders of magnitude increase in the catalytic efficiency of factor Xa that provides the physiologic pathway for thrombin generation. While the kinetic constants and the identity of peptide bonds cleaved in prothrombin to generate alpha-thrombin have been long established, the peptidyl portions of the factor Va molecule responsible for its interactions with factor Xa, prothrombin, and the lipid surface are still the subject of intense investigation. In this review, we summarize the current state of knowledge with respect to the interactions of the factor Va molecule with the various components of prothrombinase. RECENT
FINDINGS: Binding sites for factor Xa have been identified on both the heavy and light chains of factor Va. Two amino acid regions that interact with factor Xa have been delineated on the heavy chain of the cofactor. It has also been demonstrated that the carboxyl-terminal portion of the heavy chain of factor Va contains hirudin-like motifs and appears to be responsible for the interaction of factor Va with prothrombin. This region of the molecule is important for procofactor activation by thrombin as well as cofactor function. Finally, the membrane-binding site of factor Va is contributed by several elements of the light chain and involves both electrostatic and hydrophobic interactions.
SUMMARY: The absence or dysfunction of factor Va leads to hemorrhagic diseases while prolonged existence of the active cofactor species is associated with thrombosis. Thus, modulation of the incorporation of factor Va into prothrombinase in vivo by using synthetic peptides that have the potential to impair factor Va binding to any of the components of prothrombinase, will allow for control of the rate of thrombin generation at the site of vascular damage. As a consequence, a systematic definition of the regions of factor Va governing its incorporation within prothrombinase will provide the scaffold for the synthesis of potent anticoagulant molecules that could modulate thrombin formation and suppress excessive clotting in thrombotic individuals.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15725905     DOI: 10.1097/01.moh.0000155016.30296.90

Source DB:  PubMed          Journal:  Curr Opin Hematol        ISSN: 1065-6251            Impact factor:   3.284


  10 in total

1.  An anticoagulant RNA aptamer that inhibits proteinase-cofactor interactions within prothrombinase.

Authors:  Sai K Buddai; Juliana M Layzer; Genmin Lu; Christopher P Rusconi; Bruce A Sullenger; Dougald M Monroe; Sriram Krishnaswamy
Journal:  J Biol Chem       Date:  2009-12-18       Impact factor: 5.157

2.  Comprehensive N- and O-glycosylation mapping of human coagulation factor V.

Authors:  Cheng Ma; Ding Liu; Dong Li; Junping Zhang; Xiao-Qian Xu; He Zhu; Xiu-Feng Wan; Carol H Miao; Barbara A Konkle; Philip Onigman; Weidong Xiao; Lei Li
Journal:  J Thromb Haemost       Date:  2020-06-14       Impact factor: 5.824

3.  Cryo-EM structure of the prothrombin-prothrombinase complex.

Authors:  Eliza A Ruben; Brock Summers; Michael J Rau; James A J Fitzpatrick; Enrico Di Cera
Journal:  Blood       Date:  2022-06-16       Impact factor: 25.476

4.  Spellbinding Effects of the Acidic COOH-Terminus of Factor Va Heavy Chain on Prothrombinase Activity and Function.

Authors:  Jamila Hirbawi; Michael Kalafatis
Journal:  ACS Omega       Date:  2017-09-06

Review 5.  Diagnosis and Treatment of von Willebrand Disease and Rare Bleeding Disorders.

Authors:  Giancarlo Castaman; Silvia Linari
Journal:  J Clin Med       Date:  2017-04-10       Impact factor: 4.241

6.  Clinical Phenotype and Genetic Analysis of Twins With Congenital Coagulation Factor V Deficiency.

Authors:  Yanhui Wei; Yuzhuo He; Xuejun Guo
Journal:  J Pediatr Hematol Oncol       Date:  2022-03-01       Impact factor: 1.170

7.  Case Report: Novel Mutation of F5 With Maternal Uniparental Disomy Causes Severe Congenital Factor V Deficiency.

Authors:  Lin Cheng; Ying Li; Wenjuan Zhou; Tao Bo
Journal:  Front Pediatr       Date:  2022-06-07       Impact factor: 3.569

8.  Cryo-EM structures of human coagulation factors V and Va.

Authors:  Eliza A Ruben; Michael J Rau; James A J Fitzpatrick; Enrico Di Cera
Journal:  Blood       Date:  2021-06-03       Impact factor: 25.476

9.  Large subgaleal hematoma as a presentation of parahemophilia.

Authors:  Souvagya Panigrahi; Sudhansu S Mishra; Srikant Das; Sunil K Patra
Journal:  J Neurosci Rural Pract       Date:  2013-04

10.  [Factor V congenital deficiency: about a case].

Authors:  Saloua Boujrad; Brahim El Hasbaoui; Hanae Echahdi; Mohamed Malih; Aomar Agadr
Journal:  Pan Afr Med J       Date:  2017-07-06
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.